SC 13G/A 1 d866273dsc13ga.htm SC 13G/A SC 13G/A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

SCHEDULE 13G

(Rule 13d-102)

Information to be Included in Statements Filed Pursuant

to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed

Pursuant to § 240.13d-2

Under the Securities Exchange Act of 1934

(Amendment No. 3)

 

 

Marinus Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

56854Q101

(CUSIP Number)

December 31, 2019

(Date of Event Which Requires Filing of This Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

    CUSIP No. 56854Q101    

 

   13G       Page  2  of 7 Pages  

 

  1   

Names of Reporting Persons

 

Bain Capital Life Sciences Fund, L.P.

  2  

Check the Appropriate Box if a Member of a Group

(a)  ☐        (b)  ☐

 

  3  

SEC Use Only

 

    

  4  

Citizenship or Place of Organization

 

Cayman Islands

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person

With

    5    

Sole Voting Power

 

0 shares of Common Stock

   6   

Shared Voting Power

 

5,390,922 shares of Common Stock

   7   

Sole Dispositive Power

 

0 shares of Common Stock

   8   

Shared Dispositive Power

 

5,390,922 shares of Common Stock

  9  

Aggregate Amount Beneficially Owned by Each Reporting Person

 

5,390,922 shares of Common Stock

10  

Check if the Aggregate Amount in Row (9) Excludes Certain Shares

 

  ☐    

11  

Percent of Class Represented by Amount in Row 9

 

6.2%

12  

Type of Reporting Person

 

PN

 

    CUSIP No. 56854Q101    

 

   13G       Page  3  of 7 Pages  

 

  1   

Names of Reporting Persons

 

BCIP Life Sciences Associates, LP

  2  

Check the Appropriate Box if a Member of a Group

(a)  ☐        (b)  ☐

 

  3  

SEC Use Only

 

    

  4  

Citizenship or Place of Organization

 

Delaware

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person

With

    5    

Sole Voting Power

 

0 shares of Common Stock

   6   

Shared Voting Power

 

551,813 shares of Common Stock

   7   

Sole Dispositive Power

 

0 shares of Common Stock

   8   

Shared Dispositive Power

 

551,813 shares of Common Stock

  9  

Aggregate Amount Beneficially Owned by Each Reporting Person

 

551,813 shares of Common Stock

10  

Check if the Aggregate Amount in Row (9) Excludes Certain Shares

 

  ☐    

11  

Percent of Class Represented by Amount in Row 9

 

0.6%

12  

Type of Reporting Person

 

PN

Item 1(a)

Name of Issuer

The name of the issuer to which this filing on Schedule 13G relates is Marinus Pharmaceuticals, Inc. (the “Company”).

 

Item 1(b)

Address of Issuer’s Principal Executive Offices

The principal executive offices of the Company are located at 5 Radnor Corporate Center, Suite 500, 100 Matsonford Rd, Radnor, PA 19087.

 

Item 2(a)

Name of Person Filing

This Schedule 13G is being filed jointly by Bain Capital Life Sciences Fund, L.P., a Cayman exempted limited partnership (“BCLS”), and BCIP Life Sciences Associates, LP, a Delaware limited partnership (“BCIPLS” and, together with BCLS, the “Reporting Persons”).

Bain Capital Life Sciences Investors, LLC, a Delaware limited liability company (“BCLSI”), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of Bain Capital Life Sciences Partners, LP, a Cayman exempted limited partnership (“BCLSP”), which is the general partner of BCLS.

Boylston Coinvestors, LLC, a Delaware limited liability company (“Boylston”), is the general partner of BCIPLS. BCLSI governs the investment strategy and decision-making process with respect to investments held by BCIPLS.

As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by the Reporting Persons.

The Reporting Persons have entered into a Joint Filing Agreement, dated February 14, 2020, pursuant to which the Reporting Persons have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k)(1) promulgated under the Act.

 

Item 2(b)

Address of Principal Business Office or, if None, Residence:

The principal business address of each of the Reporting Persons, BCLSI, BCLSP, Boylston, Mr. Schwartz and Dr. Koppel is 200 Clarendon Street, Boston, MA 02116.

 

Item 2(c)

Citizenship

BCLS and BCLSP are organized under the laws of the Cayman Islands. BCIPLS, BCLSI and Boylston are organized under the laws of the State of Delaware. Mr. Schwartz and Dr. Koppel are citizens of the United States.

 

Item 2(d)

Title of Class of Securities

The class of securities of the Company to which this Schedule 13G relates is Common Stock, $0.001 par value per share (“Common Stock”).

 

Item 2(e)

CUSIP Number

The CUSIP number of the Common Stock is 56854Q101.

Item 3

If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a

 

  (a) ☐

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

 

  (b) ☐

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

 

  (c) ☐

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

 

  (d) ☐

Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

 

  (e) ☐

An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

 

  (f) ☐

An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

 

  (g) ☐

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

 

  (h) ☐

A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

 

  (i) ☐

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

 

  (j) ☐

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

 

  (k) ☐

Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

 

Item 4

Ownership

(a) Amount beneficially owned:

This Schedule 13G is being filed on behalf of the Reporting Persons. As of the close of business on December 31, 2019, BCLS held 5,390,922 shares of Common Stock, representing approximately 6.2% of the Company’s outstanding shares of Common Stock, and BCIPLS held 551,813 shares of Common Stock, representing approximately 0.6% of the Company’s outstanding shares of Common Stock.

As a result of the foregoing and the relationships described in Item 2(a), the Reporting Persons may be deemed to collectively beneficially own an aggregate of 5,942,735 shares of Common Stock, representing approximately 6.9% of the Company’s outstanding shares of Common Stock.

The percentage of the Company’s outstanding shares of Common Stock held by the Reporting Persons is based on 86,471,122 shares of Common Stock issued and outstanding, as reported by the Company in its prospectus supplement filed with the Securities and Exchange Commission on December 12, 2019 (after giving effect to the full exercise of the underwriters’ option to purchase additional shares of Common Stock).

(b) Percent of class:

See Item 4(a) hereof.

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

0 shares of Common Stock

(ii) Shared power to vote or to direct the vote:

 

BCLS    5,390,922 shares of Common Stock
BCIPLS    551,813 shares of Common Stock

(iii) Sole power to dispose or to direct the disposition of:

0 shares of Common Stock

(iv) Shared power to dispose or to direct the disposition of:

 

BCLS    5,390,922 shares of Common Stock
BCIPLS    551,813 shares of Common Stock

 

Item 5

Ownership of Five Percent or Less of a Class

Not applicable.

 

Item 6

Ownership of More Than Five Percent on Behalf of Another Person

Not applicable.

 

Item 7

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Not applicable.

 

Item 8

Identification and Classification of Members of the Group

Not applicable.

 

Item 9

Notice of Dissolution of Group

Not applicable.

 

Item 10

Certifications

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURES

After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information in this statement is true, complete and correct.

 

Dated: February 14, 2020     Bain Capital Life Sciences Fund, L.P.
   

By:

  

Bain Capital Life Sciences Partners, LP

its general partner

   

By:

  

Bain Capital Life Sciences Investors, LLC

its general partner

    By:  

/s/ Adam Koppel

     

Name:  Adam Koppel

     

Title:   Managing Director

    BCIP Life Sciences Associates, LP
   

By:

  

Boylston Coinvestors, LLC

its general partner

    By:  

/s/ Adam Koppel

     

Name:  Adam Koppel

     

Title:   Authorized Signatory

Exhibit A

AGREEMENT REGARDING THE JOINT FILING OF

SCHEDULE 13G

The undersigned hereby agree as follows:

(i) Each of them is individually eligible to use the Schedule 13G to which this Exhibit is attached, and such Schedule 13G is filed on behalf of each of them; and

(ii) Each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

 

Dated: February 14, 2020     Bain Capital Life Sciences Fund, L.P.
   

By:

  

Bain Capital Life Sciences Partners, LP

its general partner

   

By:

  

Bain Capital Life Sciences Investors, LLC

its general partner

    By:  

/s/ Adam Koppel

     

Name:  Adam Koppel

     

Title:   Managing Director

    BCIP Life Sciences Associates, LP
   

By:

  

Boylston Coinvestors, LLC

its general partner

    By:  

/s/ Adam Koppel

     

Name:  Adam Koppel

     

Title:   Authorized Signatory